Literature DB >> 21414953

Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial.

Giovanni Addolorato1, Lorenzo Leggio, Anna Ferrulli, Silvia Cardone, Giorgio Bedogni, Fabio Caputo, Giovanni Gasbarrini, Raffaele Landolfi.   

Abstract

AIMS: To explore the effect of baclofen in a dose of 20 mg three times per day, compared with the already studied dose of 10 mg three times per day, in the treatment of alcohol dependence.
METHODS: We present a secondary analysis of a 12-week double-blind, placebo-controlled, randomized clinical trial with two doses of baclofen, specifically 10 mg t.i.d. and 20 mg t.i.d. Out of 94 subjects consecutively screened, 42 were randomized into the study. Fourteen of the 42 patients were randomly allocated to placebo, 14 to the group treated with baclofen 10 mg t.i.d. (B10 mg) and 14 to the group treated with baclofen 20 mg t.i.d. (B20 mg).
RESULTS: Compared with patients allocated to placebo, patients allocated to the B10 mg group had a 53% reduction in the number of drinks per day (P < 0.0001) and patients allocated to the B20 mg group had a 68% reduction in the number of drinks per day (P < 0.0001), with respect to the number of drinks per day during the 28 days before randomization. The effect of baclofen 20 mg t.i.d. was greater than that of baclofen 10 mg t.i.d. (P = 0.0214, Wald test) showing a dose-effect relationship. Both doses of baclofen were well tolerated.
CONCLUSION: This is provisional evidence of a dose-response effect for baclofen in the treatment of alcohol dependence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21414953     DOI: 10.1093/alcalc/agr017

Source DB:  PubMed          Journal:  Alcohol Alcohol        ISSN: 0735-0414            Impact factor:   2.826


  69 in total

Review 1.  Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence.

Authors:  Andrew J Muzyk; Sarah K Rivelli; Jane P Gagliardi
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

Review 2.  Behavioral and Genetic Evidence for GIRK Channels in the CNS: Role in Physiology, Pathophysiology, and Drug Addiction.

Authors:  Jody Mayfield; Yuri A Blednov; R Adron Harris
Journal:  Int Rev Neurobiol       Date:  2015-06-22       Impact factor: 3.230

Review 3.  Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.

Authors:  Megan M Yardley; Lara A Ray
Journal:  Addict Biol       Date:  2016-02-01       Impact factor: 4.280

4.  Comment on: "Management of alcohol dependence in patients with liver disease".

Authors:  Benjamin Rolland; Sylvie Deheul; Alexandre Louvet; Olivier Cottencin; Régis Bordet
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

Review 5.  Future pharmacological treatments for substance use disorders.

Authors:  Ariadna Forray; Mehmet Sofuoglu
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 6.  Management of alcohol dependence in patients with liver disease.

Authors:  Giovanni Addolorato; Antonio Mirijello; Lorenzo Leggio; Anna Ferrulli; Raffaele Landolfi
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

Review 7.  Pharmacotherapy for alcoholic patients with alcoholic liver disease.

Authors:  Cynthia L Vuittonet; Michael Halse; Lorenzo Leggio; Samuel B Fricchione; Michael Brickley; Carolina L Haass-Koffler; Tonya Tavares; Robert M Swift; George A Kenna
Journal:  Am J Health Syst Pharm       Date:  2014-08-01       Impact factor: 2.637

8.  Baclofen and naltrexone effects on alcohol self-administration: Comparison of treatment initiated during abstinence or ongoing alcohol access in baboons.

Authors:  August F Holtyn; Barbara J Kaminski; Elise M Weerts
Journal:  Drug Alcohol Depend       Date:  2017-07-18       Impact factor: 4.492

Review 9.  Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?

Authors:  Patrycja Kleczkowska; Irena Smaga; Małgorzata Filip; Magdalena Bujalska-Zadrozny
Journal:  Neurotox Res       Date:  2016-08-02       Impact factor: 3.911

10.  Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection.

Authors:  L Leggio; A Ferrulli; A Zambon; F Caputo; G A Kenna; R M Swift; G Addolorato
Journal:  Addict Behav       Date:  2011-12-27       Impact factor: 3.913

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.